文献速递肿瘤 PET/CT

基线18F-FDG PET/CT代谢肿瘤负荷改善儿童成熟B细胞淋巴瘤风险分层

Metabolic tumor burden on baseline 18F-FDG PET/CT improves risk stratification in pediatric patients with mature B-cell lymphoma.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2019-06-11

该回顾性研究分析46例初诊儿童成熟B细胞非霍奇金淋巴瘤患者的治疗前18F-FDG PET/CT,评估总代谢肿瘤体积(TMTV)和总病灶糖酵解(TLG)的预后价值。中位随访31个月,TMTV和TLG均为独立预后因素,优于其他临床病理因素,可辅助风险亚分层,尤其在高危患者中。

要点

  • 基线TMTV和TLG是儿童B-NHL的强独立预后因素。
  • 高TLG(>5797 g)患者2年PFS和OS显著低于低TLG者。
  • TLG可有效亚分层高危或中危组患者。

核心结论

  • 基线TMTV和TLG均为儿童B-NHL的强独立预后因素,有助于风险亚分层,尤其在高危患者中。

研究设计与样本

  • 回顾性分析46例连续初诊儿童B-NHL患者(中位年龄7岁,范围2-18岁)的治疗前18F-FDG PET/CT。
  • 比较临床病理参数和影像特征(包括TMTV、TLG和PET/CT检测的骨髓受累)对无进展生存(PFS)和总生存(OS)的预测价值。

主要发现

  • 中位随访31个月,TMTV和TLG预测事件的曲线下面积分别为0.820和0.816。
  • 7例高TLG(>5797 g)患者2年PFS和OS分别为29%和43%,低TLG者为93%和96%(P < 0.001)。
  • 10例高TMTV(>524 cm3)患者预后显著较差(PFS:50% vs. 92%,P = 0.001;OS:60% vs. 96%,P = 0.002)。
  • 多因素分析中,TMTV和TLG优于其他临床病理因素(包括血清乳酸脱氢酶和活检骨髓受累),为最稳健的生存预测因子。
  • TLG在高危和中危组中有效亚分层,高危组阴性预测值和阳性预测值分别为100%和100%,中危组分别为92%和50%。

关键数值与推荐

  • 高TLG定义为>5797 g。
  • 高TMTV定义为>524 cm3。
  • 仅PET检测的骨髓受累预后价值低于骨髓活检。

临床怎么用

  • 基线18F-FDG PET/CT测量的TMTV和TLG可用于儿童B-NHL风险分层,辅助识别高危患者。
  • TLG可进一步在高危或中危组内亚分层,指导治疗决策。

局限性

  • 回顾性研究,样本量46例,中位随访31个月。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: In order to better identify patients most at risk of treatment failure and disease progression in pediatric mature B-cell non-Hodgkin lymphoma (B-NHL), the prognostic role of metabolic tumor burden measured on baseline 18F-FDG PET/CT scan, including total metabolic tumor volume (TMTV) and total lesion glycolysis (TLG), was investigated. METHODS: Pretreatment 18F-FDG PET/CT scans from 46 consecutive pediatric patients (median age 7 years; range 2-18 years) with newly diagnosed B-NHL were retrospectively analyzed. Clinicopathological parameters and imaging characteristics, including TMTV, TLG, and bone marrow (BM) involvement detected by PET/CT were compared to predict progression-free survival (PFS) and overall survival (OS). RESULTS: The median follow-up time was 31 months. Areas under the curve of TMTV and TLG to predict events were 0.820 and 0.816, respectively. The 2-year PFS and OS were 29% and 43% in 7 patients with high TLG (> 5797 g) vs. 93% and 96% in those with low TLG (P < 0.001). High TMTV (> 524 cm3) was present in ten patients and predicted a significantly inferior outcome (PFS: 50% vs. 92%, P = 0.001; OS: 60% vs. 96%, P = 0.002). In multivariate analysis, TMTV and TLG outperformed other clinicopathological factors, including serum lactate dehydrogenase and BM involvement on biopsy, and remained the most robust predictors of survival. Furthermore, TLG sub-stratified patients with distinct outcomes efficiently within high- or intermediate-risk groups, with the negative predictive value of 100% and 92% and the positive predictive value of 100% and 50% for high-risk and intermediate-risk patients, respectively. On the other hand, BM involvement identified only by PET demonstrated an inferior prognostic value in comparison with BM biopsy. CONCLUSIONS: Baseline TMTV and TLG are both strong independent prognostic factors for pediatric B-NHL and provide a potential approach to aid in risk sub-stratification, especially in patients with high-risk disease.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Chen S, He K, Feng F, et al. Metabolic tumor burden on baseline 18F-FDG PET/CT improves risk stratification in pediatric patients with mature B-cell lymphoma. Eur J Nucl Med Mol Imaging. 2019. PMID: 31187163. doi:10.1007/s00259-019-04363-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。